IMRX

Immuneering Stock Analysis

AI Rating

Neutral
  • Quality2/10
  • Growth↓ 4/10
  • Value↑ 5/10
Immuneering sales and earnings growth
IMRX Growth
Neutral
  • Revenue Y/Y↓ 0.00%
  • EPS Y/Y↑ 37.75%
  • FCF Y/Y↑ 17.42%
Immuneering gross and profit margin trends
IMRX Profitability
Low
  • Gross margin ↓ 0.00%
  • EPS margin↓ 0.00%
  • ROIC 5Y↓ -444.13%
Immuneering net debt vs free cash flow
IMRX Risk
Great
  • Debt / Equity↓ 0.0
  • Debt / FCF↓ 0.0
  • Interest coverage↑ 999.0

Immuneering stock is less volatile than the overall market, so it's low risk. We give it a Great risk rating.

More Biotechnology stocks ↗